New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
05:49 EDTMDTMedtronic introduces new generation Enlite glucose sensor
Medtronic announced the European launch of new generation Enlite, the latest iteration of the company's Enlite glucose sensor. New generation Enlite is designed to provide a more consistent and comfortable experience for people using continuous glucose monitoring, or CGM. Insulin pumps with built-in CGM provide more precise insulin delivery and lifestyle flexibility for people with diabetes. In addition to delivering small amounts of insulin around-the-clock, these integrated systems provide real-time glucose values and customizable alerts that give warning before glucose levels go too high or too low, prompting the person with diabetes to take preventative action.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
15:21 EDTMDTMedtronic acquisition of Covidien receives U.S. FTC clearance
Subscribe for More Information
14:28 EDTMDTMedtronic agrees to divest Covidien drug-coated balloon catheter business
Medtronic (MDT) has agreed to divest the drug-coated balloon catheter business of Covidien (COV) in order to settle Federal Trade Commission charges that its $42.9B acquisition of Covidien would likely be anticompetitive. Under the FTCís proposed settlement, Medtronic will sell the drug-coated balloon catheter business to medical device company Spectranetics (SPNC), the FTC announced. According to the FTCís complaint both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard (BCR), which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administrationís approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger, the FTC alleges. The Commission vote to accept the proposed consent order for public comment was 5-0. The FTC will publish the consent agreement package in the Federal Register shortly. The agreement will be subject to public comment for 30 days, beginning today and continuing through December 29, after which the Commission will decide whether to make the proposed consent order final.
November 21, 2014
13:31 EDTMDTCovidien announces mailing of definitive joint proxy statement, prospectus
Covidien (COV) announced, for purposes of the Irish Takeover Rules, that the definitive joint proxy statement of Covidien and Medtronic (MDT), which also serves as a prospectus of Medtronic Holdings Limited and comprises Covidienís scheme circular required under Irish law is being sent today to Covidien and Medtronic shareholders. As previously announced, on June 15, Covidien and Medtronic entered into a definitive agreement pursuant to which Medtronic Holdings Limited, a new holding company incorporated in Ireland that will be renamed Medtronic plc, will acquire Covidien and Medtronic. The joint proxy statement/prospectus will contain important information about the transaction for shareholders of both companies, as well as notices of the shareholder meetings and instructions on voting online, by mail, by telephone or in person.
November 19, 2014
08:15 EDTMDTMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
06:54 EDTMDTMedtronic reiterated as a top pick at JPMorgan
Subscribe for More Information
November 18, 2014
12:08 EDTMDTOn The Fly: Midday Wrap
Subscribe for More Information
09:08 EDTMDTMedtronic says regulatory processes for Covidien deal 'all on track'
Subscribe for More Information
08:39 EDTMDTMedtronic says 'would not be surprised' to be at high end of FY15 guidance range
Subscribe for More Information
08:39 EDTMDTMedtronic sees 2H15 gross margin 74.5%
Subscribe for More Information
08:34 EDTMDTMedtronic sees Diabetes operations to have difficult comparison in Q3
Subscribe for More Information
08:28 EDTMDTMedtronic sees U.S. approval for IMPACT Admiral balloon in Q1
Subscribe for More Information
07:20 EDTMDTMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS $4.00-$4.10, consensus $4.05
Narrows FY15 revenue guidance to up 4%-5% from 3%-5%.
07:17 EDTMDTMedtronic reports Q2 EPS 96c, consensus 96c
Subscribe for More Information
November 17, 2014
15:16 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
08:57 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 28, December is at 21, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
November 16, 2014
14:08 EDTMDTDaVita announces collaboration with Medtronic
DaVita Kidney Care, a division of DaVita HealthCare Partners (DVA) and leading provider of kidney care services, announced a collaboration with Medtronic (MDT) to better understand cardiovascular health in end stage renal disease, ESRD patients. The collaboration will focus on developing a pilot program using Medtronic's Reveal LINQ Insertable Cardiac Monitoring system to identify cardiac arrhythmias in patients receiving dialysis. "Medtronic recently announced data at the American Society of Nephrology meeting that showed a higher incidence of arrhythmias in patients receiving hemodialysis," said Ven Manda, vice president, Renal Care Solutions at Medtronic. "We are pleased to pursue this collaboration with DaVita to monitor more patients and gather additional data that will further our understanding of the relationship between dialysis and cardiac events in ESRD patients." "Given the high incidence rate of cardiovascular disease and events in ESRD patients, we believe that by collaborating with Medtronic, we can gain knowledge to help improve the lives of ESRD patients," said Mahesh Krishnan, vice president for clinical innovation and public policy for DaVita HealthCare Partners. "Through the collaboration we expect to utilize innovative monitoring technology and data from our DaVita Kidney Care information systems across the country. This effort is poised to improve the lives of patients by proactively detecting and preventing cardiac complications."
November 14, 2014
12:43 EDTMDTMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTMDTMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use